BEGIN:VCALENDAR
PRODID:-//AddEvent Inc//AddEvent.com v1.7//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:Europe/Madrid
BEGIN:STANDARD
DTSTART:20221030T020000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20220327T030000
RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DTSTAMP:20220811T123004Z
STATUS:CONFIRMED
UID:1660221004addeventcom
SEQUENCE:0
DTSTART;TZID=Europe/Madrid:20220912T130000
DTEND;TZID=Europe/Madrid:20220912T140000
SUMMARY:MPI 2001 – Clinical trials in embolotherapy and interventional oncology: Meet the PI
DESCRIPTION:Title: MPI 2001 – Clinical trials in embolotherapy and interventional oncology: Meet the PI\n\nType: Meet the PI\n\nTopics: Interventional Oncology\, Venous Intervention\n\n2022\, September 12 | 13:00 - 14:00 (Europe/Madrid)\nNews on Stage\n\nScheduled lectures:\n\n2001.1 / PiVET-ED: a prospective\, randomised\, single-blinded\, sham controlled study of pelvic vein embolisation for treatment of erectile dysfunction\n- H. Kavnoudias\n\n2001.2 / RESPECT: a new Europe-wide prospective multi-centre observational study evaluating the effectiveness of percutaneous electrochemotherapy for liver cancer\n- A. Kovács\,P. Wiggermann\n\n2001.3 / A multi-center\, single arm\, non-randomized\, prospective European trial to evaluate the safety and efficacy of the Histosonics system in the treatment of primary and metastatic liver cancers (#hope4liver)\n- T. Wah\n\n2001.4 / First in human clinical trial evaluating safety and effectiveness of investigational radiopaque Eye90 Microspheres™ for the treatment of unresectable hepatocellular carcinoma and metastatic colorectal cancer\n- A. Holden\n\nVisit https://programme.cirse2022.cirse.org to watch live and on demand!
X-ALT-DESC;FMTTYPE=text/html:Title: MPI 2001 – Clinical trials in embolotherapy and interventional oncology: Meet the PI<br><br>Type: Meet the PI<br><br>Topics: Interventional Oncology, Venous Intervention<br><br>2022, September 12 | 13:00 - 14:00 (Europe/Madrid)<br>News on Stage<br><br>Scheduled lectures:<br><br>2001.1 / PiVET-ED: a prospective, randomised, single-blinded, sham controlled study of pelvic vein embolisation for treatment of erectile dysfunction<br>- H. Kavnoudias<br><br>2001.2 / RESPECT: a new Europe-wide prospective multi-centre observational study evaluating the effectiveness of percutaneous electrochemotherapy for liver cancer<br>- A. Kovács,P. Wiggermann<br><br>2001.3 / A multi-center, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the Histosonics system in the treatment of primary and metastatic liver cancers (#hope4liver)<br>- T. Wah<br><br>2001.4 / First in human clinical trial evaluating safety and effectiveness of investigational radiopaque Eye90 Microspheres™ for the treatment of unresectable hepatocellular carcinoma and metastatic colorectal cancer<br>- A. Holden<br><br>Visit https://programme.cirse2022.cirse.org to watch live and on demand!
LOCATION:News on Stage
TRANSP:OPAQUE
END:VEVENT
END:VCALENDAR